Brazil pushes HIV remission breakthroughs and new injectable PrEP

Claims

What the coverage asserts, and how well corroborated each claim is across sources.

• [● 4 SOURCES] Fiocruz signed a memorandum of understanding with MSD to develop Alimatravir (MK‑8527), an oral PrEP still in phase‑3 trials and pending ANVISA approval. (announced by Ministry of Health)
• [● 2 SOURCES] GSK’s proposed price for cabotegravir was described by the Health Minister as “adequate”. (ministerial comment)
• [● 3 SOURCES] Remission is linked to hematopoietic stem‑cell transplants using donors with the CCR5‑delta32 mutation that blocks HIV entry. (mechanistic explanation)
• [○ 1 SOURCE] A Fiocruz trial of lenacapavir with 668 volunteers showed efficacy close to 100 % and adherence around 96 %. (clinical trial results)
• [● 3 SOURCES] The Ministry of Health has asked Conitec to incorporate the injectable PrEP cabotegravir into the SUS system by the end of the year. (government request)
• [● 3 SOURCES] Negotiations for the six‑month injectable lenacapavir failed because Gilead would not accept Brazil’s offer, even though Brazil was prepared to pay up to ten times the price offered to similar‑income‑ (statement by Health Minister)
• [● 3 SOURCES] Both patients stopped antiretroviral therapy and have remained with undetectable viral loads for 12 and 14 months. (follow‑up monitoring after transplant)
• [● 3 SOURCES] Two additional HIV remission cases were presented at the 26th International AIDS Conference, raising the worldwide total to 13. (presented at the conference)